A Noninvasive Comparison Study between Human Gliomas with IDH1 and IDH2 Mutations by MR Spectroscopy
暂无分享,去创建一个
N. Voets | P. Jezzard | S. Clare | R. Stacey | P. Plaha | C. Schofield | U. Emir | J. McCullagh | N. de Pennington | O. Ansorge | T. Cadoux-Hudson | Sarah J. Larkin | Xin Shen | J. Mccullagh
[1] M. Julià-Sapé,et al. Cancer metabolism in a snapshot: MRS(I) , 2019, NMR in biomedicine.
[2] A. Iafrate,et al. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate , 2018, Nature Communications.
[3] P. Vyas,et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. , 2017, Blood.
[4] Susan M. Chang,et al. Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma , 2017, Scientific Reports.
[5] T. Itoh,et al. Myo-inositol concentration in MR spectroscopy for differentiating high grade glioma from primary central nervous system lymphoma , 2017, Journal of Neuro-Oncology.
[6] S. Venneti,et al. Non-invasive metabolic imaging of brain tumours in the era of precision medicine , 2016, Nature Reviews Clinical Oncology.
[7] Klaus Scheffler,et al. MR spectroscopy for in vivo assessment of the oncometabolite 2‐hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T , 2016, Journal of magnetic resonance imaging : JMRI.
[8] N. Voets,et al. Improved Localization for 2-Hydroxyglutarate Detection at 3 T Using Long-TE Semi-LASER , 2016, Tomography.
[9] Haoyuan Wang,et al. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas , 2016, Journal of experimental & clinical cancer research : CR.
[10] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[11] Roland Kreis,et al. The trouble with quality filtering based on relative Cramér‐Rao lower bounds , 2016, Magnetic resonance in medicine.
[12] Peter Jezzard,et al. Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations. , 2016, Cancer research.
[13] B. Rosen,et al. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate , 2015, Clinical Cancer Research.
[14] Christian M. Metallo,et al. Metabolic consequences of oncogenic IDH mutations. , 2015, Pharmacology & therapeutics.
[15] E. Gottlieb,et al. Research into cancer metabolomics: Towards a clinical metamorphosis. , 2015, Seminars in cell & developmental biology.
[16] R. Macaulay. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. , 2015, Cancer control : journal of the Moffitt Cancer Center.
[17] T. Scheenen,et al. Multi‐center reproducibility of neurochemical profiles in the human brain at 7 T , 2015, NMR in biomedicine.
[18] L. Staudt,et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. , 2014, Blood.
[19] J. Stebbing,et al. IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. , 2013, Future oncology.
[20] W. Yung,et al. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. , 2013, Neuro-oncology.
[21] O. Abdel-Wahab,et al. The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization* , 2012, The Journal of Biological Chemistry.
[22] Hui Yang,et al. IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives , 2012, Clinical Cancer Research.
[23] W. Teeuwisse,et al. Simulations of high permittivity materials for 7 T neuroimaging and evaluation of a new barium titanate‐based dielectric , 2012, Magnetic resonance in medicine.
[24] Ovidiu C. Andronesi,et al. Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy , 2012, Science Translational Medicine.
[25] Dinesh Rakheja,et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients , 2011, Nature Medicine.
[26] Hong Wu,et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy , 2012, Journal of Neuro-Oncology.
[27] R. Hills,et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. , 2011, Blood.
[28] H. Dombret,et al. Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. , 2011, Blood.
[29] Hai Yan,et al. 2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations , 2011, PloS one.
[30] K. Kinzler,et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.
[31] A. Iafrate,et al. A Sensitive and Specific Diagnostic Panel to Distinguish Diffuse Astrocytoma From Astrocytosis: Chromosome 7 Gain With Mutant Isocitrate Dehydrogenase 1 and p53 , 2011, Journal of neuropathology and experimental neurology.
[32] M. Caligiuri,et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[34] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[35] R Gruetter,et al. Field mapping without reference scan using asymmetric echo‐planar techniques , 2000, Magnetic resonance in medicine.